Since February 2012, the FDA has identified widespread infiltration of counterfeit bevacizumab into the US drug-supply chain. This Perspectives uses this case study to highlight the continued lack of information, knowledge, and solutions necessary to protect patients against future breaches in the drug-supply network, as well as the need for collaborative efforts to enhanced surveillance for counterfeit medicines and improve communication of risk information.
- Tim K. Mackey
- Raphael Cuomo
- Bryan A. Liang
